Israel Healthcare Ventures
VC Fund
Tel Aviv, Israel
Israel Healthcare Ventures is a VC fund in Tel Aviv focused on Health Care and Medical Device. Israel HealthCare Ventures (IHCV) - a leading Israeli life sciences venture fund - was founded at the end of the year 2000. The fund is focused on providing funds (capital) to Israeli and Israeli-related companies in the fields of medical devices, pharmaceuticals, biotechnology, nanotechnology and medical-related IT.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Israel Healthcare Ventures invests in
Stages Israel Healthcare Ventures invests in
Countries Israel Healthcare Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Series D
- $1.2M–$16M
- Series F
- $19M–$40M
Investment Focus
Industry
- Health Care 4 (50%)
- Medical Device 4 (50%)
- Medical 3 (38%)
- Biotechnology 3 (38%)
- Robotics 2 (25%)
Stage
- Series D 2 (25%)
- Series F 2 (25%)
- Funding Round 2 (25%)
- Series B 1 (13%)
- Series E 1 (13%)
Country
- Israel 4 (50%)
- United States 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Avner Lushi
Partner
|
Partner | Total investments: 1 | Find email | |
|
Alona Weiss
Partner
|
Partner | Total investments: 0 | Find email | |
|
Carlo Salvi
Investment Commitee
|
Investment Commitee | Total investments: 0 | Find email | |
Daniella Horev
Administrative Manager
|
Administrative Manager | Total investments: 0 | Find email | |
Eran Perry
Partner
|
Partner | Total investments: 1 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Gamida Cell
|
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells,for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia. | $40M / Series F / Jun 19, 2017 | |
Lifeward
|
Lifeward develops, manufactures, and markets a walking system for persons with lower limb disabilities Its products include ReWalk Rehabilitation System and ReWalk Personal System. ReWalk Rehabilitation System allows walking, standing, sitting, and the capacity to ascend or descend stairs in the rehab center environment. The ReWalk Personal Systemis designed for everyday use in a range of environments. It can be used at home, work, or other locations and it functions outdoors and on different surfaces or terrains. The ReWalk Personal System allows sitting, standing, and turning as well as offers the ability to climb and descend stairs.The company changes the quality of life for individuals with lower limb disability by developing robotic technologies. Rewalk Robotics was founded on 2001 and is based in Marlborough, Massachusetts. | $1.2M / Series D / Jun 17, 2013 | |
|
Gamida Cell
|
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells,for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia. | $10M / Series E / May 15, 2012 | |
OrSense
|
OrSense is a medical device company that develops and commercializes patient monitoring solutions for non-invasive continuous measurements of hemoglobin, oxygen saturation, glucose and other blood parameters. OrSense's NBM-200MP monitors and displays oxygen saturation of Hb (SpO2), low signal oximetry, SpO2, pulse rate, plethysmogram andhemoglobin, all non-invasively and continuously. The system is designed for use in hospitals including operating and recovery rooms and intensive care units as well as in outpatient sites and emergency services. OrSense's non-invasive hemoglobin/hematocrit monitor was granted the CE approval and was tested on over 4,000 patients and donors at 15 sites in the U.S. and Europe. The Company's products are based on its proprietary Occlusion Spectroscopy technology, which overcomes key obstacles that hinder the performance of competing approaches. | $18M / May 02, 2011 | |
NovoGI
|
novoGI™ (previously NiTi Surgical Solutions) is committed to advancing patient care by providing an expanding range of comprehensive solutions for GI disease management.NiTi Surgical Solutions has developed the first major advance in closure for gastrointestinal surgery in more than 30 years.NiTi's proprietary technology represents abreakthrough in natural healing with tissue-sparing, uniform BioDynamix anastomosis. The company's unique line of products utilizes Nitinol-based elements to press together the ends of resected tissue, enabling a natural reconnection of the intestine after removing a section, for example, as part of a colon cancer treatment. The company is commercializing a family of FDA-cleared and CE-marked disposable tissue closure devices. | $18.5M / Series F / Aug 11, 2009 | |
|
Gamida Cell
|
Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells,for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia. | $16M / Series D / Sep 27, 2006 | |
Mazor Robotics
|
Mazor Robotics is a spine surgery innovator—inspiring the art of surgery with guidance systems and complementary products that provide a safer surgical environment for patients, surgeons, and OR staff. Renaissance, Mazor Robotics’ new guidance system, is transforming spine surgery from freehand procedures to highly-accurate, state-of-the-artprocedures that raise the standard of care with better clinical outcomes.The company was founded by Professor Moshe Shoham and Mr. Eli Zehavi in 2001 and is headquartered in Cesarea, Israel. | $10M / Series B / May 04, 2005 | |
GI-View
|
GI View Ltd. develops devices for diagnosing and treating gastrointestinal disorders. Its product includes Aer-O-Scope, a disposable, miniaturized, self-propelling, and self-navigating endoscope, which provides video images of the colon inner surface that are displayed on a screen for real time viewing. The company was founded in 2004 and is basedin Ramat Gan, Israel. | $7M / Sep 05, 2004 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Israel Healthcare Ventures invest in?
Israel Healthcare Ventures invests primarily in Health Care, Medical Device and Medical startups, most often at Series D and Series F stage. Most of the 8 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Israel Healthcare Ventures's check size?
Israel Healthcare Ventures typically joins rounds of $1.2M–$16M at Series D and $19M–$40M at Series F. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Israel Healthcare Ventures participates in.
How do I contact Israel Healthcare Ventures?
Public channels for Israel Healthcare Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Israel Healthcare Ventures?
The team at Israel Healthcare Ventures includes Avner Lushi (Partner), Alona Weiss (Partner) and Carlo Salvi (Investment Commitee), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
